BackARS Pharmaceuticals Overview

ARS Pharmaceuticals Total Liabilities

Latest total liabilities for SPRY: $240M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$236.98M
↑ 95.61% YoYΔ $115.83M vs prior year quarter

Peer trimmed avg / median

Loading

ARS Pharmaceuticals Total Liabilities History

Loading

ARS Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

ARS Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ARS Pharmaceuticals (SPRY) FAQ

As of the most recent data (June 2026), SPRY shows a total liabilities of $240M. That compares with $120M in the prior-year period — up 95.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SPRY's total liabilities is now $240M (was $120M) — a 95.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ARS Pharmaceuticals is outperforming or lagging.

Tracking SPRY's total liabilities over time shows whether ARS Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $240M That compares with $120M in the prior-year period — up 95.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has ARS Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $240M) with ownership activity and broader fundamentals.

ARS Pharmaceuticals's total liabilities is $240M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.